Targeting adipose tissue in the treatment of obesity-associated diabetes

Nature Reviews Drug Discovery

Volumn 15, Issue 9, 2016, Pages 639-660

  Kusminski, Christine M ^a   Bickel, Perry E ^a   Scherer, Philipp E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA GLUCOSIDASE INHIBITOR; AMFEBUTAMONE PLUS NALTREXONE; CARBONATE DEHYDRATASE INHIBITOR; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTOKINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FIBROBLAST GROWTH FACTOR 21; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; JANUS KINASE 2; LEPTIN; LIRAGLUTIDE; LORCASERIN; MEGLITINIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENTERMINE PLUS TOPIRAMATE; RETINOL BINDING PROTEIN 4; SCLEROPROTEIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; STAT3 PROTEIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

APOPTOSIS; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DEPRESSION; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DIZZINESS; DRUG TARGETING; DYSGEUSIA; ENERGY METABOLISM; EXERCISE; FIBROSIS; FLUID RETENTION; FRACTURE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEADACHE; HUMAN; HYPOGLYCEMIA; INFLAMMATION; INSOMNIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LIVER FAILURE; METABOLIC REGULATION; NAUSEA; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARESTHESIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HOMEOSTASIS; PATHOLOGY; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; OBESITY;

EID: 84973115747     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.75     Document Type: Review

References (313)

1. Van Gaal, L. F., Mertens, I. L., & De Block, C. E. Mechanisms linking obesity with cardiovascular disease. Nature 444, 875-880 (2006
2. Kusminski, C. M., Shetty, S., Orci, L., Unger, R. H., & Scherer, P. E. Diabetes and apoptosis: lipotoxicity. Apoptosis 14, 1484-1495 (2009
3. Scherer, P. E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55, 1537-1545 (2006
4. Sun, K., Kusminski, C. M., & Scherer, P. E. Adipose tissue remodeling and obesity. J. Clin. Invest. 121, 2094-2101 (2011
5. Unger, R. H., & Scherer, P. E. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol. Metab. 21, 345-352 (2010
6. Kusminski, C. M., & Scherer, P. E. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol. Metab. 23, 435-443 (2012
7. Sun, K., Tordjman, J., Clement, K., & Scherer, P. E. Fibrosis and adipose tissue dysfunction. Cell Metab. 18, 470-477 (2013
8. Rosen, E. D., & Spiegelman, B. M. What we talk about when we talk about fat. Cell 156, 20-44 (2014
9. Rutkowski, J. M., Stern, J. H., & Scherer, P. E. The cell biology of fat expansion. J. Cell Biol. 208, 501-512 (2015
10. Frayn, K. N., Karpe, F., Fielding, B. A., Macdonald, I. A., & Coppack, S. W. Integrative physiology of human adipose tissue. Int. J. Obes. Relat. Metab. Disord. 27, 875-888 (2003
11. Lee, M. J., Wu, Y., & Fried, S. K. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol. Aspects Med. 34, 1-11 (2013
12. Tchkonia, T., et al. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab. 17, 644-656 (2013
13. Tchkonia, T., et al. Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am. J. Physiol. Endocrinol. Metab. 292, E298-E307 (2007
14. Cawthorn, W. P., Scheller, E. L., & MacDougald, O. A. Adipose tissue stem cells meet preadipocyte commitment: going back to the future. J. Lipid Res. 53, 227-246 (2012
15. Staszkiewicz, J., Gimble, J. M., Manuel, J. A., & Gawronska-Kozak, B. IFATS collection: stem cell antigen 1 positive ear mesenchymal stem cells display enhanced adipogenic potential. Stem Cells 26, 2666-2673 (2008
16. Rosen, E. D., & Spiegelman, B. M. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276, 37731-37734 (2001
17. Farmer, S. R. Transcriptional control of adipocyte formation. Cell Metab. 4, 263-273 (2006
18. Tontonoz, P., & Spiegelman, B. M. Fat and beyond: the diverse biology of PPARγ. Annu. Rev. Biochem. 77, 289-312 (2008
19. Altiok, S., Xu, M., & Spiegelman, B M. PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11, 1987-1998 (1997
20. Tontonoz, P., Hu, E., & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-Activated transcription factor. Cell 79, 1147-1156 (1994
21. Wang, Q. A., et al. Distinct regulatory mechanisms governing embryonic versus adult adipocyte maturation. Nat. Cell Biol. 17, 1099-1111 (2015
22. Gupta, R. K., et al. Transcriptional control of preadipocyte determination by Zfp423. Nature 464, 619-623 (2010
23. Vishvanath, L., et al. Pdgfrβ+ mural preadipocytes contribute to adipocyte hyperplasia induced by high-fat-diet feeding and prolonged cold exposure in adult mice. Cell Metab. 23, 350-359 (2015
24. Spalding, K. L., et al. Dynamics of fat cell turnover in humans. Nature 453, 783-787 (2008
25. Fasshauer, M., & Bluher, M. Adipokines in health and disease. Trends Pharmacol. Sci. 36, 461-470 (2015
26. Holland, W. L., & Summers, S. A. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 29, 381-402 (2008
27. Flier, J. S., Cook, K. S., Usher, P., & Spiegelman, B. M. Severely impaired adipsin expression in genetic and acquired obesity. Science 237, 405-408 (1987
28. Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. Adipose expression of tumor necrosis factor-Alpha: direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993
29. Zhang, Y., et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432 (1994
30. Scherer, P. E., Williams, S., Fogliano, M., Baldini, G., & Lodish, H. F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270, 26746-26749 (1995
31. Friedman, J. 20 years of leptin: leptin at 20: an overview. J. Endocrinol. 223, T1-T8 (2014
32. Farooqi, I. S., & O'Rahilly, S. Leptin: a pivotal regulator of human energy homeostasis. Am. J. Clin. Nutr. 89, 980S-984S (2009
33. Williams, K. W., & Elmquist, J. K. From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior. Nat. Neurosci. 15, 1350-1355 (2012
34. Kusminski, C. M., & Scherer, P. E. Leptin beyond the lipostat: key component of blood pressure regulation. Circ. Res. 116, 1293-1295 (2015
35. Ye, R., & Scherer, P. E. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol. Metab. 2, 133-141 (2013
36. Shetty, S., Kusminski, C. M., & Scherer, P. E. Adiponectin in health and disease: evaluation of adiponectin-Targeted drug development strategies. Trends Pharmacol. Sci. 30, 234-239 (2009
37. Pajvani, U. B., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 279, 12152-12162 (2004
38. Turer, A. T., & Scherer, P. E. Adiponectin: mechanistic insights and clinical implications. Diabetologia 55, 2319-2326 (2012
39. Yamauchi, T., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769 (2003
40. Holland, W. L., et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 17, 55-63 (2011
41. Hug, C., et al. T cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl Acad. Sci. USA 101, 10308-10313 (2004
42. Denzel, M. S., et al. T cadherin is critical for adiponectin-mediated cardioprotection in mice. J. Clin. Invest. 120, 4342-4352 (2010
43. Matsuda, K., et al. Positive feedback regulation between adiponectin and T cadherin impacts adiponectin levels in tissue and plasma of male mice. Endocrinology 156, 934-946 (2015
44. Hui, X., et al. Adiponectin enhances cold-induced browning of subcutaneous adipose tissue via promoting M2 macrophage proliferation. Cell Metab. 22, 279-290 (2015
45. Hotta, K., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20, 1595-1599 (2000
46. Turer, A. T., et al. Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia 54, 2515-2524 (2011
47. Combs, T. P., et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145, 367-383 (2004
48. Yamauchi, T., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941-946 (2001
49. Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7, 947-953 (2001
50. Iwabu, M., et al. Adiponectin and AdipoR1 regulate PGC 1α and mitochondria by Ca2+ and AMPK/SIRT1. Nature 464, 1313-1319 (2010
51. Okamoto, M., et al. Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 51, 827-835 (2008
52. Kim, C. H., et al. MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness. Am. J. Physiol. Endocrinol. Metab. 291, E298-E305 (2006
53. Li, R., Lau, W. B., & Ma, X. L. Adiponectin resistance and vascular dysfunction in the hyperlipidemic state. Acta Pharmacol. Sin. 31, 1258-1266 (2010
54. Kim, J. Y., et al. Obesity-Associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117, 2621-2637 (2007
55. Prins, J. B., & O'Rahilly, S. Regulation of adipose cell number in man. Clin. Sci. (Lond.) 92, 3-11 (1997
56. Wang, Q. A., Tao, C., Gupta, R. K., & Scherer, P. E. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat. Med. 19, 1338-1344 (2013
57. Tchoukalova, Y. D., et al. Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. Proc. Natl Acad. Sci. USA 107, 18226-18231 (2010
58. Ryden, M., et al. Transplanted bone marrow-derived cells contribute to human adipogenesis. Cell Metab. 22, 408-417 (2015
59. Lackey, D. E., & Olefsky, J. M. Regulation of metabolism by the innate immune system. Nat. Rev. Endocrinol. 12, 15-28 (2016
60. Weisberg, S. P., et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808 (2003
61. Xu, H., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830 (2003
62. Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184 (2007
63. Patsouris, D., et al. Ablation of CD11c positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 8, 301-309 (2008
64. Cinti, S., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46, 2347-2355 (2005
65. Wernstedt Asterholm, I., et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 20, 103-118 (2014
66. Ricard-Blum, S. The collagen family. Cold Spring Harb. Perspect. Biol. 3, a004978 (2011
67. Iyengar, P., et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J. Clin. Invest. 115, 1163-1176 (2005
68. Khan, T., et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol. Cell. Biol. 29, 1575-1591 (2009
69. Trayhurn, P. Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity. Annu. Rev. Nutr. 34, 207-236 (2014
70. Krishnan, J., et al. Dietary obesity-Associated Hif1α activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Genes Dev. 26, 259-270 (2012
71. Halberg, N., et al. Hypoxia-inducible factor 1α induces fibrosis and insulin resistance in white adipose tissue. Mol. Cell. Biol. 29, 4467-4483 (2009
72. Sun, K., Halberg, N., Khan, M., Magalang, U. J., & Scherer, P. E. Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction. Mol. Cell. Biol. 33, 904-917 (2013
73. Colberg, S. R., et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 33, e147-e167 (2010
74. Knowler, W. C., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002
75. Linden, M. A., Pincu, Y., Martin, S. A., Woods, J. A., & Baynard, T. Moderate exercise training provides modest protection against adipose tissue inflammatory gene expression in response to high-fat feeding. Physiol. Rep. 2, e12071 (2014
76. Reinehr, T. Lifestyle intervention in childhood obesity: changes and challenges. Nat. Rev. Endocrinol. 9, 607-614 (2013
77. Stanford, K. I., et al. A novel role for subcutaneous adipose tissue in exercise-induced improvements in glucose homeostasis. Diabetes 64, 2002-2014 (2015
78. Guh, D. P., et al. The incidence of co morbidities related to obesity and overweight: a systematic review and meta-Analysis. BMC Publ. Health 9, 88 (2009
79. American Diabetes Association. 6. Obesity management for the treatment of type 2 diabetes. Diabetes Care 39 (Suppl. 1), S47-S51 (2016
80. Astrup, A., et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP 1 analog, liraglutide. Int. J. Obes (Lond.) 36, 843-854 (2012
81. Pi Sunyer, X., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373, 11-22 (2015
82. Sumithran, P., & Proietto, J. Benefit-risk assessment of orlistat in the treatment of obesity. Drug Saf. 37, 597-608 (2014
83. Smith, S. R., et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363, 245-256 (2010
84. Verrotti, A., et al. Topiramate-induced weight loss: a review. Epilepsy Res. 95, 189-199 (2011
85. Greenway, F. L., et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376, 595-605 (2010
86. Ornellas, T., & Chavez, B. Naltrexone SR/bupropion SR (contrave): a new approach to weight loss in obese adults. P T 36, 255-262 (2011
87. Ismail-Beigi, F., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419-430 (2010
88. [No authors listed.] Introduction. Diabetes Care 39 (Suppl. 1), S1-S2 (2016
89. Pryor, R., & Cabreiro, F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem. J. 471, 307-322 (2015
90. Turner, R. C., Cull, C. A., Frighi, V., & Holman, R. R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281, 2005-2012 (1999
91. Drucker, D. J., & Nauck, M. A. The incretin system: glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705 (2006
92. Amori, R. E., Lau, J., & Pittas, A. G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-Analysis. JAMA 298, 194-206 (2007
93. Yki-Jarvinen, H. Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118 (2004
94. Nawrocki, A. R., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-Activated receptor γ agonists. J. Biol. Chem. 281, 2654-2660 (2006
95. Zhang, Q., Dou, J., & Lu, J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-Analyses. Diabetes Res. Clin. Pract. 105, 313-321 (2014
96. Zinman, B., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117-2128 (2015
97. Phillippe, H. M., & Wargo, K. A. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. Ann. Pharmacother. 44, 1615-1623 (2010
98. Mulvihill, E. E., & Drucker, D. J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase 4 inhibitors. Endocr. Rev. 35, 992-1019 (2014
99. DiNicolantonio, J. J., Bhutani, J., & O'Keefe, J. H. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart 2, e000327 (2015
100. DeFronzo, R. A., Davidson, J. A., & Del Prato, S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 14, 5-14 (2012
101. Finan, B., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5, 209ra151 (2013
102. Finan, B., et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27-36 (2015
103. Challa, T. D., et al. Regulation of adipocyte formation by GLP 1/GLP 1R signaling. J. Biol. Chem. 287, 6421-6430 (2012
104. Shao, Y., Yuan, G., Zhang, J., & Guo, X. Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression. Drug Des. Devel. Ther. 9, 1177-1184 (2015
105. Topol, E. J., et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376, 517-523 (2010
106. Lehr, S., Hartwig, S., & Sell, H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteom. Clin. Appl. 6, 91-101 (2012
107. Dahlman, I., et al. Functional annotation of the human fat cell secretome. Arch. Physiol. Biochem. 118, 84-91 (2012
108. Ahima, R. S., Saper, C. B., Flier, J. S., & Elmquist, J. K. Leptin regulation of neuroendocrine systems. Front. Neuroendocrinol. 21, 263-307 (2000
109. Myers, M. G. Jr. et al. Challenges and opportunities of defining clinical leptin resistance. Cell Metab. 15, 150-156 (2012
110. Heymsfield, S. B., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282, 1568-1575 (1999
111. Mittendorfer, B., et al. Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes 60, 1474-1477 (2011
112. Hukshorn, C. J., et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG OB) administration in obese men. J. Clin. Endocrinol. Metab. 85, 4003-4009 (2000
113. Hoffmann, A., et al. Leptin dose-dependently decreases atherosclerosis by attenuation of hypercholesterolemia and induction of adiponectin. Biochim. Biophys. Acta 1862, 113-120 (2015
114. Dodd, G. T., et al. Leptin and insulin act on POMC neurons to promote the browning of white fat. Cell 160, 88-104 (2015
115. Farooqi, I. S., et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341, 879-884 (1999
116. Akinci, G., & Akinci, B. Metreleptin treatment in patients with non-HIV associated lipodystrophy. Recent Pat. Endocr. Metab. Immune Drug Discov. 9, 74-78 (2015
117. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00673387 (2008
118. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01235741 (2010
119. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00265980 (2005
120. Kissileff, H. R., et al. Leptin reverses declines in satiation in weight-reduced obese humans. Am. J. Clin. Nutr. 95, 309-317 (2012
121. Rosenbaum, M., & Leibel, R. L. 20 years of leptin: role of leptin in energy homeostasis in humans. J. Endocrinol. 223, T83-T96 (2014
122. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00085982 (2004
123. Oral, E. A., et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570-578 (2002
124. Ogawa, A., Harris, V., McCorkle, S. K., Unger, R. H., & Luskey, K. L. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J. Clin. Invest. 85, 973-976 (1990
125. Roth, J. D., et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl Acad. Sci. USA 105, 7257-7262 (2008
126. Wang, M. Y., et al. Leptin therapy in insulin-deficient type I diabetes. Proc. Natl Acad. Sci. USA 107, 4813-4819 (2010
127. Unger, R. H., & Roth, M. G. A new biology of diabetes revealed by leptin. Cell Metab. 21, 15-20 (2015
128. Shimabukuro, M., Zhou, Y. T., Levi, M., & Unger, R. H. Fatty acid-induced β cell apoptosis: a link between obesity and diabetes. Proc. Natl Acad. Sci. USA 95, 2498-2502 (1998
129. Shpilman, M., et al. Development and characterization of high affinity leptins and leptin antagonists. J. Biol. Chem. 286, 4429-4442 (2011
130. Elinav, E., et al. Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity. Endocrinology 150, 3083-3091 (2009
131. Kadowaki, T., Yamauchi, T., & Kubota, N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett. 582, 74-80 (2008
132. Holland, W. L., et al. An FGF21-Adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17, 790-797 (2013
133. Xia, J. Y., et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab. 22, 266-278 (2015
134. Asterholm, I. W., & Scherer, P. E. Enhanced metabolic flexibility associated with elevated adiponectin levels. Am. J. Pathol. 176, 1364-1376 (2010
135. Halberg, N., et al. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 58, 1961-1970 (2009
136. Okada-Iwabu, M., et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503, 493-499 (2013
137. Tanabe, H., et al. Crystal structures of the human adiponectin receptors. Nature 520, 312-316 (2015
138. Ealey, K. N., Kaludjerovic, J., Archer, M. C., & Ward, W. E. Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp. Biol. Med. (Maywood) 233, 1546-1553 (2008
139. Yore, M. M., et al. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell 159, 318-332 (2014
140. Markan, K. R., et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63, 4057-4063 (2014
141. Owen, B. M., Mangelsdorf, D. J., & Kliewer, S. A. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab. 26, 22-29 (2015
142. Kliewer, S. A., & Mangelsdorf, D. J. Fibroblast growth factor 21: from pharmacology to physiology. Am. J. Clin. Nutr. 91, 254S-257S (2010
143. Ding, X., et al. βklotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 16, 387-393 (2012
144. Fisher, F. M., & Maratos-Flier, E. Understanding the physiology of FGF21. Annu. Rev. Physiol. 10, 223-241 (2015
145. Xu, J., et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-Association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297, E1105-E1114 (2009
146. Coskun, T., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149, 6018-6027 (2008
147. Kharitonenkov, A., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor 21. Endocrinology 148, 774-781 (2007
148. Fisher, F. M., et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 147, 1073-1083.e6 (2014
149. Owen, B. M., et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 20, 670-677 (2014
150. Talukdar, S., et al. FGF21 regulates sweet and alcohol preference. Cell Metab. 23, 344-349 (2015
151. Adams, A. C., et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2, 31-37 (2012
152. Lin, Z., et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17, 779-789 (2013
153. Fisher, F. M., et al. FGF21 regulates PGC 1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26, 271-281 (2012
154. Gimeno, R. E., & Moller, D. E. FGF21 based pharmacotherapy-potential utility for metabolic disorders. Trends Endocrinol. Metab. 25, 303-311 (2014
155. Gaich, G., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333-340 (2013
156. Dong, J. Q., et al. Pharmacokinetics and pharmacodynamics of PF 05231023, a novel long-Acting FGF21 mimetic, in a first in human study. Br. J. Clin. Pharmacol. 80, 1051-1063 (2015
157. Kharitonenkov, A., et al. Rational design of a fibroblast growth factor 21 based clinical candidate, LY2405319. PLoS ONE 8, e58575 (2013
158. Adams, A. C., et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS ONE 8, e65763 (2013
159. Kim, J. H., et al. Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function. Diabetes Obes. Metab. 17, 161-169 (2015
160. Talukdar, S., et al. A long-Acting FGF21 molecule, PF 05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23, 427-440 (2016
161. Weng, Y., et al. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF 05231023 in diet-induced obese and leptin-deficient obese mice. PLoS ONE 10, e0119104 (2015
162. Wu, S., Levenson, A., Kharitonenkov, A., & De Luca, F. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J. Biol. Chem. 287, 26060-26067 (2012
163. Wei, W., et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-Activated receptor γ. Proc. Natl Acad. Sci. USA 109, 3143-3148 (2012
164. Owen, B. M., et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat. Med. 19, 1153-1156 (2013
165. Bookout, A. L., et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat. Med. 19, 1147-1152 (2013
166. Lee, P., et al. Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans? Osteoporos. Int. 24, 3053-3057 (2013
167. Tseng, Y. H., et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature 454, 1000-1004 (2008
168. Townsend, K. L., et al. Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway. FASEB J. 26, 2187-2196 (2012
169. Zeng, J., Jiang, Y., Xiang, S., & Chen, B. Serum bone morphogenetic protein 7, insulin resistance, and insulin secretion in non-diabetic individuals. Diabetes Res. Clin. Pract. 93, e21-e24 (2011
170. Vaccaro, A. R., et al. The safety and efficacy of OP 1 (rhBMP 7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4 year follow up of a pilot study. Spine J. 8, 457-465 (2008
171. Bing, C. Is interleukin 1β a culprit in macrophage-Adipocyte crosstalk in obesity? Adipocyte 4, 149-152 (2015
172. Gao, D., et al. Interleukin 1β mediates macrophage-induced impairment of insulin signaling in human primary adipocytes. Am. J. Physiol. Endocrinol. Metab. 307, E289-E304 (2014
173. Handa, M., et al. XOMA 052, an anti IL 1β monoclonal antibody, prevents IL 1β mediated insulin resistance in 3T3 L1 adipocytes. Obesity (Silver Spring) 21, 306-309 (2013
174. Larsen, C. M., et al. Interleukin 1 receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007
175. van Asseldonk, E. J., et al. One week treatment with the IL 1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clin. Immunol. 160, 155-162 (2015
176. Rissanen, A., Howard, C. P., Botha, J., Thuren, T., & Global, I. Effect of anti IL 1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes. Metab. 14, 1088-1096 (2012
177. Cannon, B., & Nedergaard, J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 84, 277-359 (2004
178. Wu, J., et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150, 366-376 (2012
179. Heaton, J. M. The distribution of brown adipose tissue in the human. J. Anat. 112, 35-39 (1972
180. Cypess, A. M., et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509-1517 (2009
181. van Marken Lichtenbelt, W. D., et al. Cold-Activated brown adipose tissue in healthy men. N. Engl. J. Med. 360, 1500-1508 (2009
182. Virtanen, K. A., et al. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 360, 1518-1525 (2009
183. Flynn, A., et al. Contrast-enhanced ultrasound: a novel noninvasive, nonionizing method for the detection of brown adipose tissue in humans. J. Am. Soc. Echocardiogr. 28, 1247-1254 (2015
184. Peirce, V., Carobbio, S., & Vidal-Puig, A. The different shades of fat. Nature 510, 76-83 (2014
185. Stock, M. J., & Rothwell, N. J. Role of brown adipose tissue thermogenesis in overfeeding: a review. J. R. Soc. Med. 76, 71-73 (1983
186. Nedergaard, J., Bengtsson, T., & Cannon, B. Three years with adult human brown adipose tissue. Ann. NY Acad. Sci. 1212, E20-E36 (2010
187. Bartelt, A., et al. Brown adipose tissue activity controls triglyceride clearance. Nat. Med. 17, 200-205 (2011
188. Peirce, V., & Vidal-Puig, A. Regulation of glucose homoeostasis by brown adipose tissue. Lancet Diabetes Endocrinol. 1, 353-360 (2013
189. Geerling, J. J., et al. Metformin lowers plasma triglycerides by promoting VLDL-Triglyceride clearance by brown adipose tissue in mice. Diabetes 63, 880-891 (2014
190. Baxter, J. D., & Webb, P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat. Rev. Drug Discov. 8, 308-320 (2009
191. Blondin, D. P., et al. Increased brown adipose tissue oxidative capacity in cold-Acclimated humans. J. Clin. Endocrinol. Metab. 99, E438-E446 (2014
192. Yoneshiro, T., et al. Recruited brown adipose tissue as an antiobesity agent in humans. J. Clin. Invest. 123, 3404-3408 (2013
193. Chen, K. Y., et al. Brown fat activation mediates cold-induced thermogenesis in adult humans in response to a mild decrease in ambient temperature. J. Clin. Endocrinol. Metab. 98, E1218-E1223 (2013
194. Matsushita, M., et al. Impact of brown adipose tissue on body fatness and glucose metabolism in healthy humans. Int. J. Obes. (Lond.) 38, 812-817 (2014
195. Chondronikola, M., et al. Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans. Diabetes 63, 4089-4099 (2014
196. Orava, J., et al. Blunted metabolic responses to cold and insulin stimulation in brown adipose tissue of obese humans. Obesity (Silver Spring) 21, 2279-2287 (2013
197. Whittle, A., Relat-Pardo, J., & Vidal-Puig, A. Pharmacological strategies for targeting BAT thermogenesis. Trends Pharmacol. Sci. 34, 347-355 (2013
198. Ghorbani, M., & Himms-Hagen, J. Appearance of brown adipocytes in white adipose tissue during CL 316, 243 induced reversal of obesity and diabetes in Zucker fa/fa rats. Int. J. Obes Relat. Metab. Disord. 21, 465-475 (1997
199. Cypess, A. M., et al. Cold but not sympathomimetics activates human brown adipose tissue in vivo. Proc. Natl Acad. Sci. USA 109, 10001-10005 (2012
200. Vosselman, M. J., et al. Systemic β-Adrenergic stimulation of thermogenesis is not accompanied by brown adipose tissue activity in humans. Diabetes 61, 3106-3113 (2012
201. Carey, A. L., et al. Ephedrine activates brown adipose tissue in lean but not obese humans. Diabetologia 56, 147-155 (2013
202. Cypess, A. M., et al. Activation of human brown adipose tissue by a β3 adrenergic receptor agonist. Cell Metab. 21, 33-38 (2015
203. Colman, E. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma. Regul. Toxicol. Pharmacol. 48, 115-117 (2007
204. Perry, R. J., et al. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-Targeted mitochondrial uncoupler. Cell Metab. 18, 740-748 (2013
205. Perry, R. J., Zhang, D., Zhang, X. M., Boyer, J. L., & Shulman, G. I. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 347, 1253-1256 (2015
206. Bostrom, P., et al. A PGC1 α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463-468 (2012
207. Albrecht, E., et al. Irisin-A myth rather than an exercise-inducible myokine. Sci. Rep. 5, 8889 (2015
208. Raschke, S., et al. Evidence against a beneficial effect of irisin in humans. PLoS ONE 8, e73680 (2013
209. Lee, P., et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 19, 302-309 (2014
210. Jedrychowski, M. P., et al. Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metab. 22, 734-740 (2015
211. Rao, R. R., et al. Meteorin-like is a hormone that regulates immune-Adipose interactions to increase beige fat thermogenesis. Cell 157, 1279-1291 (2014
212. Cohen, P., et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell 156, 304-316 (2014
213. Kong, X., et al IRF4 is a key thermogenic transcriptional partner of PGC 1α. Cell 158, 69-83 (2014
214. Kazak, L., et al. A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell 163, 643-655 (2015
215. Whittle, A. J., et al. BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell 149, 871-885 (2012
216. Fang, S., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21, 159-165 (2015
217. Sun, K., et al. Dichotomous effects of VEGF A on adipose tissue dysfunction. Proc. Natl Acad. Sci. USA 109, 5874-5879 (2012
218. Kusminski, C. M., Park, J., & Scherer, P. E. MitoNEET-mediated effects on browning of white adipose tissue. Nat. Commun. 5, 3962 (2014
219. Qiu, Y., et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 157, 1292-1308 (2014
220. Nguyen, K. D., et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 480, 104-108 (2011
221. Kolumam, G., et al. Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1/βklotho complex. eBioMedicine 2, 730-743 (2015
222. Douris, N., et al. Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology 156, 2470-2481 (2015
223. Veniant, M. M., et al. Pharmacologic effects of FGF21 are independent of the browning of white adipose tissue. Cell Metab. 21, 731-738 (2015
224. Samms, R. J., et al. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep. 11, 991-999 (2015
225. McDonald, M. E., et al. Myocardin-related transcription factor A regulates conversion of progenitors to beige adipocytes. Cell 160, 105-118 (2015
226. Evans, R. M., Barish, G. D., & Wang, Y. X. PPARs and the complex journey to obesity. Nat. Med. 10, 355-361 (2004
227. Choi, J. H., et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5. Nature 466, 451-456 (2010
228. Dhavan, R., & Tsai, L. H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2, 749-759 (2001
229. Banks, A. S., et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ. Nature 517, 391-395 (2015
230. Flaherty, K. T., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012
231. Nemoto, S., Fergusson, M. M., & Finkel, T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC 1α. J. Biol. Chem. 280, 16456-16460 (2005
232. Wilson, B. J., Tremblay, A. M., Deblois, G., Sylvain-Drolet, G., & Giguere, V. An acetylation switch modulates the transcriptional activity of estrogen-related receptor α. Mol. Endocrinol. 24, 1349-1358 (2010
233. Picard, F., et al Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature 429, 771-776 (2004
234. Mayoral, R., et al. Adipocyte SIRT1 knockout promotes PPARγ activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity. Mol. Metab. 4, 378-391 (2015
235. Qiang, L., et al. Brown remodeling of white adipose tissue by SirT1 dependent deacetylation of Pparγ. Cell 150, 620-632 (2012
236. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00920556 (2009
237. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT02247596 (2014
238. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01714102 (2012
239. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01038089 (2009
240. Dash, S., Xiao, C., Morgantini, C., Szeto, L., & Lewis, G. F. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler. Thromb. Vasc. Biol. 33, 2895-2901 (2013
241. Knop, F. K., et al. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet. Med. 30, 1214-1218 (2013
242. Chen, S., et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-Alcoholic fatty liver disease: a randomized controlled trial. Dig. Liver Dis. 47, 226-232 (2015
243. Brasnyo, P., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106, 383-389 (2011
244. Muise, E. S., et al. Adipose fibroblast growth factor 21 is up regulated by peroxisome proliferator-Activated receptor γ and altered metabolic states. Mol. Pharmacol. 74, 403-412 (2008
245. Wang, H., Qiang, L., & Farmer, S. R. Identification of a domain within peroxisome proliferator-Activated receptor γ regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol. Cell. Biol. 28, 188-200 (2008
246. Dutchak, P. A., et al. Fibroblast growth factor 21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556-567 (2012
247. Wahli, W., & Michalik, L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol. Metab. 23, 351-363 (2012
248. Odegaard, J. I., et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 447, 1116-1120 (2007
249. Feuerer, M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930-939 (2009
250. Cipolletta, D., et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486, 549-553 (2012
251. Chiang, S. H., et al. The protein kinase IKKe regulates energy balance in obese mice. Cell 138, 961-975 (2009
252. Ussher, J. R., et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 59, 2453-2464 (2010
253. Pedersen, D. J., et al. A major role of insulin in promoting obesity-Associated adipose tissue inflammation. Mol. Metab. 4, 507-518 (2015
254. Reilly, S. M., et al. An inhibitor of the protein kinases TBK1 and IKK-e improves obesity-related metabolic dysfunctions in mice. Nat. Med. 19, 313-321 (2013
255. Makino, H., Saijo, T., Ashida, Y., Kuriki, H., & Maki, Y. Mechanism of action of an antiallergic agent, amlexanox (AA 673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase. Int. Arch. Allergy Appl. Immunol. 82, 66-71 (1987
256. Reilly, S. M., et al. A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis. Nat. Commun. 6, 6047 (2015
257. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01842282 (2013
258. Stanley, T. L., et al. TNF-α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J. Clin. Endocrinol. Metab. 96, E146-E150 (2011
259. Dominguez, H., et al. Metabolic and vascular effects of tumor necrosis factor-Alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 42, 517-525 (2005
260. Solomon, D. H., et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 305, 2525-2531 (2011
261. Paquot, N., Castillo, M. J., Lefebvre, P. J., & Scheen, A. J. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 85, 1316-1319 (2000
262. Anderson, K., Wherle, L., Park, M., Nelson, K., & Nguyen, L. Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies. Am. Health Drug Benefits 7, 231-235 (2014
263. Goldfine, A. B., et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 159, 1-12 (2013
264. Koska, J., et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 52, 385-393 (2009
265. Goldfine, A. B., et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin. Transl. Sci. 1, 36-43 (2008
266. Barzilay, J. I., et al. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes. Diabetes Care 37, 1083-1091 (2014
267. Penesova, A., et al. Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo-controlled trial in subjects without diabetes. Diabetes Obes. Metab. 17, 608-612 (2015
268. Raghavan, R. P., Laight, D. W., & Cummings, M. H. Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. Int. J. Clin. Pract. 68, 271-277 (2014
269. Oh, D. Y., et al. GPR120 is an omega 3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142, 687-698 (2010
270. Oh da, Y., et al. A Gpr120 selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat. Med. 20, 942-947 (2014
271. Sullivan, T. J., et al. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism 62, 1623-1632 (2013
272. Di Prospero, N. A., et al. CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Diabetes Obes. Metab. 16, 1055-1064 (2014
273. de Zeeuw, D., et al. The effect of CCR2 inhibitor CCX140 B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol. 3, 687-696 (2015
274. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00699790 (2008
275. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01712061 (2012
276. Xue, C. B., et al. Discovery of INCB8761/PF 4136309, a potent, selective, and orally bioavailable CCR2 antagonist. ACS Med. Chem. Lett. 2, 913-918 (2011
277. Filgueiras, L. R., Serezani, C. H., & Jancar, S. Leukotriene B4 as a potential therapeutic target for the treatment of metabolic disorders. Front. Immunol. 6, 515 (2015
278. Li, P., et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat. Med. 21, 239-247 (2015
279. Liston, T. E., et al. Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP 105, 696 in man following single oral administration. Br. J. Clin. Pharmacol. 45, 115-121 (1998
280. Favalli, E. G., et al. Serious infections during anti-TNFα treatment in rheumatoid arthritis patients. Autoimmun Rev. 8, 266-273 (2009
281. Park, J., & Scherer, P. E. Adipocyte-derived endotrophin promotes malignant tumor progression. J. Clin. Invest. 122, 4243-4256 (2012
282. Sun, K., et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat. Commun. 5, 3485 (2014
283. Iwayama, T., et al. PDGFRα signaling drives adipose tissue fibrosis by targeting progenitor cell plasticity. Genes Dev. 29, 1106-1119 (2015
284. Haak, A. J., et al. Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J. Pharmacol. Exp. Ther. 349, 480-486 (2014
285. Sisson, T. H., et al. Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis. Am. J. Pathol. 185, 969-986 (2015
286. Lee, S. H., et al. ROCK1 isoform-specific deletion reveals a role for diet-induced insulin resistance. Am. J. Physiol. Endocrinol. Metab. 306, E332-E343 (2014
287. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00120718 (2005
288. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00498615 (2007
289. Vila, I. K., et al. Immune cell Toll-like receptor 4 mediates the development of obesity-And endotoxemia-Associated adipose tissue fibrosis. Cell Rep. 7, 1116-1129 (2014
290. Jia, L., et al. Hepatocyte Toll-like receptor 4 regulates obesity-induced inflammation and insulin resistance. Nat. Commun. 5, 3878 (2014
291. Falchook, G. S., et al. Targeting hypoxia-inducible factor 1α (HIF 1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget 5, 10280-10292 (2014
292. Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., & Powis, G. Antitumor activity and pharmacodynamic properties of PX 478, an inhibitor of hypoxia-inducible factor 1α. Mol. Cancer Ther. 3, 233-244 (2004
293. Baker, L. C., et al. The HIF-pathway inhibitor NSC 134754 induces metabolic changes and anti-Tumour activity while maintaining vascular function. Br. J. Cancer 106, 1638-1647 (2012
294. Xia, Y., Choi, H. K., & Lee, K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur. J. Med. Chem. 49, 24-40 (2012
295. Montgomery, M. K., & Turner, N. Mitochondrial dysfunction and insulin resistance: an update. Endocr. Connect. 4, R1-R15 (2015
296. Choo, H. J., et al. Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia 49, 784-791 (2006
297. Heinonen, S., et al. Impaired mitochondrial biogenesis in adipose tissue in acquired obesity. Diabetes 64, 3135-3145 (2015
298. Chattopadhyay, M., et al. Enhanced ROS production and oxidative damage in subcutaneous white adipose tissue mitochondria in obese and type 2 diabetes subjects. Mol. Cell. Biochem. 399, 95-103 (2015
299. Wilson-Fritch, L., et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J. Clin. Invest. 114, 1281-1289 (2004
300. Liu, J., et al. Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: hope from natural mitochondrial nutrients. Adv. Drug Deliv. Rev. 61, 1343-1352 (2009
301. Armstrong, J. S. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br. J. Pharmacol. 151, 1154-1165 (2007
302. Shen, W., et al. R α-lipoic acid and acetyl-l carnitine complementarily promote mitochondrial biogenesis in murine 3T3 L1 adipocytes. Diabetologia 51, 165-174 (2008
303. Kusminski, C. M., et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat. Med. 18, 1539-1549 (2012
304. Vernochet, C., et al. Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice against obesity and insulin resistance. Cell Metab. 16, 765-776 (2012
305. McLaughlin, T., Lamendola, C., Liu, A., & Abbasi, F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J. Clin. Endocrinol. Metab. 96, E1756-E1760 (2011
306. Snijder, M. B., et al. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. Am. J. Clin. Nutr. 77, 1192-1197 (2003
307. Denis, G. V., & Obin, M. S. ?Metabolically healthy obesity?: origins and implications. Mol. Aspects Med. 34, 59-70 (2013
308. Amit, M., et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev. Biol. 227, 271-278 (2000
309. Gurtner, G. C., Werner, S., Barrandon, Y., & Longaker, M. T. Wound repair and regeneration. Nature 453, 314-321 (2008
310. Cao, M., et al. Adipose-derived mesenchymal stem cells improve glucose homeostasis in high-fat diet-induced obese mice. Stem Cell Res. Ther. 6, 208 (2015
311. Shang, Q., et al. Delivery of adipose-derived stem cells attenuates adipose tissue inflammation and insulin resistance in obese mice through remodeling macrophage phenotypes. Stem Cells Dev. 24, 2052-2064 (2015
312. Zhang, Q., Liu, L. N., Yong, Q., Deng, J. C., & Cao, W. G. Intralesional injection of adipose-derived stem cells reduces hypertrophic scarring in a rabbit ear model. Stem Cell Res. Ther. 6, 145 (2015
313. Badimon, L., Onate, B., & Vilahur, G. Adipose-derived mesenchymal stem cells and their reparative potential in ischemic heart disease. Rev. Esp. Cardiol. (Engl. Ed) 68, 599-611 (2015